Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Presentation TCT 2024

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

Presenter: David Kandzari

October 28, 2024

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

L.A. McKeown

April 16, 2024

Presentation TCT 2023

TARGET Clinical Trial Program (Alcohol-Mediated Renal Denervation)

Presenter: David Kandzari

October 25, 2023

Presentation TCT 2023

SPYRAL Clinical Trial Program (Radio-Frequency Renal Denervation)

Presenter: David Kandzari

October 25, 2023

News Conference News TCT 2023

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

L.A. McKeown

October 25, 2023

Presentation TCT 2023

Securing Reimbursement: The Pathway to Financial Stability

Presenter: David Kandzari

October 24, 2023

News Conference News CRT 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Yael L. Maxwell

February 28, 2023

News Daily News

Reduction in BP Drives Treatment Preference for Hypertensive Patients

Michael O'Riordan

December 20, 2022

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Todd Neale

November 09, 2022

News Features

Cardiac Care Feels Staffing Crunch as Big Money Converts COVID-19 Travelers

Shelley Wood

January 20, 2021

News Opinion Editor's Corner

The Biggest News of 2020: TCTMD’s Top 10

Shelley Wood

December 28, 2020

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

Presentation TCT 2019

The Target BP Program: Ongoing and Future Studies

Presenter: David Kandzari

September 27, 2019

News Daily News

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

L.A. McKeown

June 19, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Conference News TCT 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Todd Neale

September 25, 2018

News Conference News EuroPCR 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Michael O'Riordan

May 23, 2018

News Conference News EuroPCR 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Shelley Wood

May 17, 2018

News Daily News

Vascular Stents an Option for Some Patients with Fibrosing Mediastinitis

March 29, 2011

CME

Advertisement

Long-term Safety and Efficacy of Radiofrequency Renal Denervation in the Presence of Antihypertensive Drugs: 24-Month Results From the SPYRAL HTN-ON MED Randomized Trial

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

TARGET Clinical Trial Program (Alcohol-Mediated Renal Denervation)

SPYRAL Clinical Trial Program (Radio-Frequency Renal Denervation)

LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI

Securing Reimbursement: The Pathway to Financial Stability

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Reduction in BP Drives Treatment Preference for Hypertensive Patients

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

Cardiac Care Feels Staffing Crunch as Big Money Converts COVID-19 Travelers

The Biggest News of 2020: TCTMD’s Top 10

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

The Target BP Program: Ongoing and Future Studies

FDA Advisors Face ‘Forest of Dueling Numbers’ at Paclitaxel PAD Device Review: Day One

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

Vascular Stents an Option for Some Patients with Fibrosing Mediastinitis

Latest Data in Renal Denervation

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content